8-K: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results, Highlights Clinical Data and New Loan Agreement

Inhibrx Biosciences reports its Q4 and FY 2024 financial results, highlighting clinical trial data for ozekibart and a new $100 million loan agreement with Oxford Finance LLC.

Summary

• Inhibrx Biosciences reported its financial results for the fourth quarter and fiscal year 2024.
• The company completed the sale of INBRX-101 to Sanofi S.A. and a spin-off in May 2024.
• Inhibrx now has two programs in ongoing clinical trials, with data readouts expected within the next 12 months.
• On January 13, 2025, Inhibrx entered into a loan and security agreement with Oxford Finance LLC, receiving $100 million in gross proceeds.
• An additional $50 million may be funded at the lender's discretion.
• On January 21, 2025, the company announced interim data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for colorectal cancer, showing promising results.
• As of December 31, 2024, Inhibrx had $152.6 million in cash and cash equivalents, which increased to $230.5 million by February 28, 2025, after the Oxford loan.
• Research and development expenses were $33.4 million in Q4 2024, compared to $82.1 million in Q4 2023.
• General and administrative expenses were $16.7 million in Q4 2024, compared to $7.8 million in Q4 2023.
• Net loss for Q4 2024 was $47.9 million, or $3.09 per share, compared to a net loss of $93.6 million, or $6.93 per share, in Q4 2023.
• Net income for fiscal year 2024 was $1.7 billion, or $114.01 per share, compared to a net loss of $241.4 million, or $20.48 per share, in fiscal year 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the secured loan, promising clinical data, and improved cash position, offset by the Q4 net loss and increased expenses.

Positives

• The $100 million loan from Oxford Finance LLC strengthens Inhibrx's financial position.
• The interim data from the Phase 1 trial of ozekibart (INBRX-109) shows promising efficacy in treating advanced colorectal cancer.
• The company has a strong cash position of $230.5 million as of February 2025.
• The company reported net income of $1.7 billion for fiscal year 2024, driven by the spin-off transaction.

Negatives

• The company reported a net loss of $47.9 million for the fourth quarter of 2024.
• General and administrative expenses increased significantly in Q4 2024 and for the full year, primarily due to spin-off related costs and legal proceedings.

Risks

• The company's ability to secure the additional $50 million from Oxford Finance LLC is at the lender's discretion.
• Clinical trial results may not be replicated in larger studies.
• The company's future financial performance depends on the success of its clinical programs and its ability to raise additional capital.
• The company is subject to risks and uncertainties inherent in the biopharmaceutical industry, including regulatory hurdles and competition.

Future Outlook

The company expects data readouts for its two ongoing clinical trials within the next 12 months and is initiating a new expansion cohort to validate findings in a more uniform patient population.

Industry Context

Inhibrx is operating in the competitive biopharmaceutical industry, focusing on developing novel biologic therapeutic candidates. The company's focus on protein engineering and multivalent formats aligns with current trends in drug development.

Comparison to Industry Standards

• It is difficult to compare Inhibrx's results directly to industry standards without knowing the specific stage and focus of its clinical programs.
• However, companies like Regeneron and Amgen, which also focus on biologics, serve as benchmarks for innovation and clinical development success.
• The $100 million loan secured by Inhibrx is a common financing strategy for clinical-stage biopharmaceutical companies.

Legal Proceedings

• The company incurred legal expenses related to legal proceedings, which have since concluded, finding the company not liable for damages.

Stakeholder Impact

• Shareholders may be positively impacted by the improved financial position and promising clinical data.
• Employees may benefit from the company's continued growth and development.
• Patients may benefit from the development of new therapeutic candidates.

Next Steps

• Inhibrx will continue to advance its clinical programs for ozekibart (INBRX-109) and INBRX-106.
• The company will enroll up to 50 patients in a new expansion cohort for the Phase 1 trial of ozekibart, with data anticipated in the third quarter of 2025.
• The company will make payments of interest on the Oxford loan through February 1, 2028, with principal payments beginning on March 1, 2028.

Key Dates